Partner with us
We're actively working with investors, hospitals, and diagnostic labs to fund and run clinical pilots.
Three tracks
We're raising to build the next engineering model, run clinical pilots, and complete regulatory groundwork. Request the investor briefing.
Partnership here means capital and conviction: funding the engineering roadmap, the pilot programmes that generate real-world session data, and the CDSCO Class B pathway that carries the device toward the clinic. Detailed materials are shared under NDA.
Pilot VeinMate Assist in real settings and help shape a tool built around clinical workflow.
Partnership here means running the device where access actually happens — critical care, oncology day-care, dialysis and renal units, wards, and paediatrics — and giving us the frank clinical feedback that shapes the workflow. Your team stays in control of every access; we learn how the tool earns its place at the bedside. See where it helps
High-volume phlebotomy is where reliable first-attempt access pays off fastest. Let's talk about a pilot.
Partnership here means putting the device to work across busy draw stations, where small gains in first-attempt reliability compound across thousands of patients. We'll scope a pilot around your throughput, staffing, and sample-quality goals.
Traction
We have signed letters of intent with clinical and laboratory partners, a manufacturing partner engaged for production, and further partnerships in progress. Details available under NDA in a briefing.
Process
Every engagement is collaborative and staged. We move at the pace your governance and clinical teams need.
We walk your team through the device, the evidence roadmap, and where things stand — traction, technical detail, and performance targets shared confidentially.
Together we define the setting, the clinicians involved, and what a meaningful pilot looks like for you — including governance, consent, and data handling.
We provide engineering units and hands-on training so your clinicians can use VeinMate Assist confidently within their existing workflow.
The device captures structured, auditable records of each guided session, giving both teams a clear, shared picture of how it performs in practice.
We sit down with your team to review what the data shows, what clinicians experienced, and what to refine — informing the next iteration.
Fit
The best pilots come from teams who want to build this with us, not just try it.
Why now
Forest Bloom is taking VeinMate Assist from a working prototype to clinical pilots — the stage where partners matter most.
The design patent is granted, the utility patent is filed and pending, and the CDSCO Class B regulatory pathway is in progress. This is the window where the right hospitals, labs, and investors can help shape the device before it scales, and see it in real settings first.
VeinMate Assist is an investigational device. It is not approved for sale or clinical use, and all performance figures are engineering targets under validation.
Questions
No. This site is informational only. Briefings and materials are shared directly with interested parties, and investor details are provided under NDA — it is not a solicitation or offer of securities.
No. VeinMate Assist is an investigational device and is not approved for sale or clinical use. It is progressing along the CDSCO Class B regulatory pathway.
Under NDA we share traction details, technical materials, and the performance targets we're validating — enough for your team to assess a pilot or investment seriously.
Request a briefing using the form below. Tell us who you are and what you're interested in, and we'll follow up with the right materials.
Request a briefing
Tell us who you are and what you're interested in. We'll follow up with the right materials.
This form does not collect or store medical data.
